#6719 ACUTE KIDNEY INJURY AND MULTIPLE MYELOMA-THE ROLE CYTOGENETICS: A COHORT STUDY

Abstract Background and Aims Multiple myeloma(MM) is the 2nd most common haematological neoplasm a largely heterogeneous malignancy in what regards cytogenetics, clinical presentation, therapy response overall survival. Renal impairment related to MM known be diagnosed at least 50% of patients during course this disease. Recent studies have shown an association between high-risk cytogenetic abnormalities(CA) with lower disease-free survival However, there still scarce knowledge kidney implications CA. The purpose study identify profile acute injury(AKI) presentation. Method This was single-centre retrospective cohort all adult Jan./2018-Dec./2021 tertiary care university hospital Lisbon. Diagnosis made according International Myeloma Working Group criteria. Patient variables were collected from individual records. Categorical described as total number % continuous median(P25-P75). Normally distributed compared Student-t-test, non-normally Mann-Whitney U-test categorical chi-squared test. A multivariable backward stepwise regression model performed investigate predictors for AKI. Statistical significance defined p<0.05. Analyses statistical software package STATA 16.0. Results 114 included[median age 69.8±11.4 years, 48.1% male, 90.4% caucasian]. 61.5% had hypertension, 21.2% diabetes 33.9% CKD baseline GFR 75.2(49.5-92.3)mL/min/1.73m2. 25% on RAAS inhibitors, 5.8% NSAID 9.6% bisphosphonate. heavy chain IgG(58.8%), light Kappa(52.4%) 12.8% isolated chain-MM. 56.5% Revised Staging System(R-ISS) 2. Median serum M component 4.5(2.8-7.9)g/dL, dFLC 247.8(48.9-1059.2) mg/L plasma cells bone marrow(BM) aspirate 39.0(15.5-67.0)%. 15.4% hypercalcaemia, 68.9% Bence Jones protein, 3.8% secondary amyloidosis 18.3% extramedulary 38 CA: 36.5% primary, 35.6% 33.7% high risk Most treated proteasome inhibitors(75.0%), 26.9% submitted BM transplant 59.2% complete or very good partial treatment. 13(12.5%) relapsed 26(25.0%) died. AKI present 31.1% 11.7% needed renal replacement therapy.On univariable analysis, impact (34.3% vs 15.5%, p = 0.03), (62.5% 21.1%, p<0.001), hypercalcemia (28.1% 9.9%, 0.018), higher R-ISS (p<0.001), beta 2-mycroglobulin (p 0.002) 0.01), (p<0.001) presence CA (53.1% 28.2%, 0.015), primary 0.015) (46.9% 0.064). On CA[OR 3.094 (1.018-9.403), 0.046] previous CKD[OR 8.069(2.430-26.796), 0.001] showed independent Conclusion Our suggests which may implicate worse survival, treatment highlights need prevention early diagnosis.MM cytogenetics being studied since 2000s research going attempt creating that can guide prevention, predict outcomes. It particularly diagnosis associated best our knowledge, potential has not been thoroughly studied.